93 related articles for article (PubMed ID: 23527529)
1. The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway.
Smith S; Hoyt J; Whitebread N; Manna J; Peluso M; Faia K; Campbell V; Tremblay M; Nair S; Grogan M; Castro A; Campbell M; Ferguson J; Arsenault B; Nevejans J; Carter B; Lee J; Dunbar J; McGovern K; Read M; Adams J; Constan A; Loewen G; Sydor J; Palombella V; Soglia J
Xenobiotica; 2013 Oct; 43(10):875-85. PubMed ID: 23527529
[TBL] [Abstract][Full Text] [Related]
2. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
5. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species.
Kalgutkar AS; Choo E; Taylor TJ; Marfat A
Xenobiotica; 2004 Aug; 34(8):755-70. PubMed ID: 15690763
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).
Tremblay MR; Lescarbeau A; Grogan MJ; Tan E; Lin G; Austad BC; Yu LC; Behnke ML; Nair SJ; Hagel M; White K; Conley J; Manna JD; Alvarez-Diez TM; Hoyt J; Woodward CN; Sydor JR; Pink M; MacDougall J; Campbell MJ; Cushing J; Ferguson J; Curtis MS; McGovern K; Read MA; Palombella VJ; Adams J; Castro AC
J Med Chem; 2009 Jul; 52(14):4400-18. PubMed ID: 19522463
[TBL] [Abstract][Full Text] [Related]
7. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
[TBL] [Abstract][Full Text] [Related]
8. Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor.
Xiang H; McSurdy-Freed J; Moorthy GS; Hugger E; Bambal R; Han C; Ferrer S; Gargallo D; Davis CB
J Pharm Sci; 2006 Dec; 95(12):2657-72. PubMed ID: 16892205
[TBL] [Abstract][Full Text] [Related]
9. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERĪ± covalent antagonist (SERCA).
Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
[TBL] [Abstract][Full Text] [Related]
10. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation.
Ye Q; Jiang M; Huang WT; Ling Y; Olson SH; Sun D; Xu G; Yan X; Wong BK; Jin L
Xenobiotica; 2015; 45(8):681-92. PubMed ID: 25798742
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
14. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
[TBL] [Abstract][Full Text] [Related]
16. Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists.
Tremblay MR; Nevalainen M; Nair SJ; Porter JR; Castro AC; Behnke ML; Yu LC; Hagel M; White K; Faia K; Grenier L; Campbell MJ; Cushing J; Woodward CN; Hoyt J; Foley MA; Read MA; Sydor JR; Tong JK; Palombella VJ; McGovern K; Adams J
J Med Chem; 2008 Nov; 51(21):6646-9. PubMed ID: 18842035
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
Zhou L; Dockens RC; Liu-Kreyche P; Grossman SJ; Iyer RA
Drug Metab Dispos; 2012 Jun; 40(6):1093-103. PubMed ID: 22381334
[TBL] [Abstract][Full Text] [Related]
18. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
[TBL] [Abstract][Full Text] [Related]
19. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
